*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.
Partner with the Alnylam Assist™ support team
Once you and your doctor decide to begin treatment with OXLUMO® (lumasiran),
Alnylam Assist™ is here to support you and your family in your treatment journey.
PELs can help:
-
Support you with disease education
-
Connect you to additional resources
-
Provide you with product information
-
Answer questions about treatment with OXLUMO
Learn from an Alnylam Patient Education Liaison (PEL)
PELs have backgrounds in nursing and are experienced in educating patients and families about PH1 and providing information about treatment with OXLUMO.
The purpose of the Alnylam Patient Education Liaisons (PEL) program is to provide education for patients, their families, and caregivers. PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team.
PELs do not provide medical care or advice. All diagnosis and treatment decisions should be made by you and your doctor.
Alnylam Assist™ is here to help
Alnylam offers a personalized support program for patients receiving OXLUMO. Support services include:
- An Alnylam Case Manager:
Alnylam Case Managers can help you locate resources and answer questions about getting started on treatment with OXLUMO - Help navigating insurance benefits:
Alnylam Assist can help you and your family understand your insurance coverage during treatment
- Financial assistance:
Patients who qualify may be eligible for commercial copay assistance or other financial assistance programs*
Individuals must meet specified criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.
Complete the Start Form
Once you and your healthcare provider make the decision to begin treatment, initiate the process for receiving therapy and enroll in Alnylam Assist™ by completing the Start Form.
Alnylam Assist™ is here to help you on your treatment journey
In-home nursing support
If your insurance coverage allows, you may be able to have a healthcare professional administer OXLUMO in your home.†
We’re here to help. Please reach out with questions.
Call: 1-833-256-2748 Monday-Friday, 8 AM-6 PM ET
Once you and your doctor have decided to start treatment with OXLUMO, you can call Alnylam Assist™ to find out if you may be eligible for at‑home administration based on your insurance coverage.
Frequently asked questions about OXLUMO
- Who can take OXLUMO?
-
OXLUMO is a prescription medicine for the treatment of primary hyperoxaluria type 1 (PH1) to lower oxalate in urine in children and adults. Your doctor will determine if OXLUMO is right for you.
- What is OXLUMO and how does it work?
-
OXLUMO is a prescription medicine for the treatment of PH1 to lower oxalate in urine in children and adults.
- OXLUMO targets the GO enzyme—a liver enzyme involved in making oxalate
- OXLUMO reduces levels of the GO enzyme so that less oxalate is made and sent to the kidneys
- What are the most common side effects of OXLUMO?
-
The most common side effects of OXLUMO are injection site reaction (including redness, pain, itching, or swelling at the site of the injection) and abdominal pain (including stomach pain or discomfort). These are not all the possible side effects of OXLUMO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.
- How is OXLUMO given?
-
OXLUMO is an injection administered by a healthcare provider. OXLUMO is injected under the skin. Injection sites can include the area under the skin on the abdomen, thighs, or upper arms.
Dosing of OXLUMO is based on the patient’s weight. Dosing happens in 2 phases:
-
Four starting doses are given 1 month apart at the start of treatment to help bring urinary oxalate levels down
-
Ongoing dosing is quarterly (every 3 months) or monthly, depending on the patient’s weight
-
For children under 10 kg (22 lb), 1 DOSE EVERY MONTH
-
For patients weighing 10 kg (22 lb) or more, 1 DOSE EVERY 3 MONTHS
-
OXLUMO can cause injection site reactions. Symptoms included redness, pain, itching, or swelling at the site of injection.
-
- How can Alnylam Assist™ help me?
-
Alnylam Assist™ is here to help patients who are prescribed OXLUMO.
Resources available through Alnylam Assist™ include:
- An Alnylam Case Manager
- Help navigating insurance benefits
- Financial assistance, including commercial copay assistance or other financial assistance programs for eligible patients*
A trained Alnylam Patient Education Liaison (PEL)† is available to help you learn more about PH1 and OXLUMO. Visit the Alnylam Assist™ website to learn more.
Individuals must meet specified criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.
PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team.
Other resources and organizations
You and your family may find the following sites and organizations helpful.
We hope you find the resources mentioned here helpful. Alnylam Pharmaceuticals is not affiliated with these organizations. By listing these resources, Alnylam Pharmaceuticals is not endorsing any particular service or group, and we are not responsible for the content of these sites or services. They are provided for informational purposes and should not replace your doctor’s medical advice.
CONNECT WITH AN ALNYLAM EDUCATOR
Learn about primary hyperoxaluria type 1 (PH1) and treatment with OXLUMO® from one of our trained Alnylam Patient Education Liaisons (PELs).
PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team.
